Rapid determination of platelet alloantigen genotypes by polymerase chain reaction using allele‐specific primers

Abstract

The use of allele-specific PCR for platelet alloantigen typing should facilitate the development of DNA-based typing in other regional blood centers and clinical laboratories.

Genetic typing of human platelet antigen 1 (HPA‐1) by oligonucleotide ligation assay in a specific and reliable semi‐automated system

“…The PCR-ASO dot-blot hybridization is time-consuming and depends on critical conditions needed for allele-specific hybridization based on a single base-pair difference. In addition, the method may be affected by variations in sample condition or quality of the PCR products and is sensitive for variations in hybridization temperatures and hybridization buffer conditions (Skogen et al, 1994). PCR-SSP is a fast one-stage technique; however, it carries the risk of false positive amplification.…”

CRISPR/Cas9-mediated conversion of human platelet alloantigen allotypes

“…Despite the availability of numerous DNA-based platforms for the rapid genotyping of each of the HPAs, [15][16][17][18][19] identification of a platelet alloantigen-specific antibody in the maternal sera is still required to make a positive diagnosis of NAIT, 10 and, less commonly, for posttransfusion refractoriness. 20 Determination of antibody specificity, and in some cases titer, is also critical for guiding prenatal treatment to reduce the likelihood of prenatal bleeding and intracranial hemorrhage in utero, facilitating postnatal management, and managing future pregnancies.…”

Platelet antibody identification: toward a solution

“…2 Ponatinib, a third-generation TKI, is so far the only registered TKI that shows activity against all clones expressing mutant BCR-ABL1 proteins at a single residue, including those derived from the T315I-mutated allele, which is able to confer resistance to all other approved TKIs. 3 In this issue of Blood, Deininger et al report new interesting observations about the role of mutations in determining resistance to ponatinib and also provide new information about the biology of the Ph-positive leukemias.…”

“…Platelet alloantigen phenotyping is mainly limited to human platelet alloantigen (HPA)-1a typing, as prototype antisera for the other allotypes are rare and difficult to obtain. By introduction of easy-to-use genotyping techniques, 3 the problem with platelet antigen typing is overcome. Because of genetic polymorphism or point mutations, discrepancy between pheno-and genotyping can occur and give a false interpretation of the typing results; however, such cases are rare.…”